Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy

References

• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.
   Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-Term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824. doi: 10.1200/JCO.19.01073
   PubMed Web of Science ®Google Scholar
• Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the nordic lymphoma group. Leuk Lymphoma. 2008;49(1):102–112. doi:10.1080/10428190701704647
   PubMed Web of Science ®Google Scholar
• Kimby E, Ostenstad B, Brown P, et al. Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma. 2015;56(9):2598–2607. doi:10.3109/10428194.2015.1014363
   PubMed Web of Science ®Google Scholar
• Lockmer S, Ostenstad B, Hagberg H, et al. Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of follow-Up. J Clin Oncol. 2018;36(33): 3315-3323:JCO1800262. doi:10.1200/JCO.18.00262
   Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma After rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–2522. doi:10.1200/JCO.2014.59.7534
   PubMed Web of Science ®Google Scholar
• Moccia AA, Schar S, Hayoz S, et al. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the swiss group for clinical cancer research (SAKK). Br J Haematol. 2021;192(6):1031–1034. doi:10.1111/bjh.17045
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. doi:10.1200/JCO.2008.21.3991
   PubMed Web of Science ®Google Scholar
• Kimby E, Lockmer S, Holte H, et al. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy. Br J Haematol. 2020;191(5):738–747. doi:10.1111/bjh.16692
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. doi:10.1182/blood-2003-12-4434
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957–2964. doi:10.1182/blood-2006-04-018218
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 2009;94(1):70–77. doi:10.3324/haematol.13574
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169–2174. doi:10.1182/blood-2005-04-1565
   PubMed Web of Science ®Google Scholar
• Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012; Oct122(10):3424–3431. doi:10.1172/JCI63186
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Sundstrom C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res. 2011;17(12):4136–4144. doi:10.1158/1078-0432.CCR-11-0264
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26(3):440–446. doi:10.1200/JCO.2007.12.8298
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784–5789. doi:10.1158/1078-0432.CCR-07-0778
   PubMed Web of Science ®Google Scholar
• Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017;1(22):1884–1890. doi:10.1182/bloodadvances.2016000786
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–2169. doi:10.1056/NEJMoa041869
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25(4):390–398. doi:10.1200/JCO.2006.06.1648
   PubMed Web of Science ®Google Scholar
• Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549–561. doi:10.1016/S1470-2045(18)30102-5
   PubMed Web of Science ®Google Scholar
• O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126–3129. doi:10.1182/blood-2008-05-154013
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122. doi:10.1016/S1470-2045(15)00169-2
   PubMed Web of Science ®Google Scholar
• Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017;130(13):1491–1498. doi:10.1182/blood-2017-07-737353
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57(1):289–300. doi:10.1111/j.2517-6161.1995.tb02031.x
   Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Soft. 2010;33(1):1–22. doi:10.18637/jss.v033.i01
   PubMed Web of Science ®Google Scholar
• Simon N, Friedman J, Hastie T, et al. Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13. doi:10.18637/jss.v039.i05
   PubMed Web of Science ®Google Scholar
• Durinck S, Moreau Y, Kasprzyk A, et al. BioMart and bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005;21(16):3439–3440. doi:10.1093/bioinformatics/bti525
   PubMed Web of Science ®Google Scholar
• Durinck S, Spellman PT, Birney E, et al. Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomaRt. Nat Protoc. 2009;4(8):1184–1191. doi:10.1038/nprot.2009.97
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41. doi:10.1186/gb-2011-12-4-r41
   PubMed Web of Science ®Google Scholar
• Van Loo P, Nordgard SH, Lingjaerde OC, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107(39):16910–16915. 28doi:10.1073/pnas.1009843107
   PubMed Web of Science ®Google Scholar
• Nilsen G, Liestol K, Van Loo P, et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics. 2012;13:591. doi:10.1186/1471-2164-13-591
   PubMed Web of Science ®Google Scholar
• Tobin JWD, Keane C, Gunawardana J, et al. Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. J Clin Oncol. 2019;37(34):3300–3309. doi:10.1200/JCO.18.02365
   PubMed Web of Science ®Google Scholar
• Bouska A, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 2014;123(11):1681–1690. doi:10.1182/blood-2013-05-500595
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Delaney A, Ben-Neriah S, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49(8):669–681. doi:10.1002/gcc.20780
   PubMed Web of Science ®Google Scholar
• Bohdanowicz M, Balkin DM, De Camilli P, et al. Recruitment of OCRL and Inpp5B to phagosomes by Rab5 and APPL1 depletes phosphoinositides and attenuates akt signaling. Mol Biol Cell. 2012;23(1):176–187. doi:10.1091/mbc.E11-06-0489
   PubMed Web of Science ®Google Scholar
• Perez-Alea M, Vivancos A, Caratu G, et al. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget. 2016;7(19):28086–28095. doi:10.18632/oncotarget.8578
   PubMedGoogle Scholar
• Droubi A, Wallis C, Anderson KE, et al. The inositol 5-phosphatase INPP5B regulates B cell receptor clustering and signaling. J Cell Biol. 2022;221(9):e202112018 doi:10.1083/jcb.202112018
   PubMed Web of Science ®Google Scholar
• Deeb SJ, D'Souza RC, Cox J, et al. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012;11(5):77–89. doi:10.1074/mcp.M111.015362
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856. doi:10.1200/JCO.2014.60.2383
   PubMed Web of Science ®Google Scholar
• Leich E, Ott G, Rosenwald A. Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract Res Clin Haematol. 2011; 24(2):95–109. doi:10.1016/j.beha.2011.02.003
   PubMed Web of Science ®Google Scholar
• Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114(4):826–834. doi:10.1182/blood-2009-01-198580
   PubMed Web of Science ®Google Scholar
• Hao S, Lin P, Medeiros LJ, et al. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol. 2017;30(10):1378–1386. doi:10.1038/modpathol.2017.63
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Formigaro L, Cavallari M, et al. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. Oncotarget. 2017;8(17):28008–28020. doi:10.18632/oncotarget.15883
   PubMedGoogle Scholar
• Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol. 2010; 22(5):424–430. doi:10.1097/CCO.0b013e32833d5938
   PubMed Web of Science ®Google Scholar
• Lockmer S, Ren W, Brodtkorb M, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259–267. doi:10.1111/bjh.16159
   PubMed Web of Science ®Google Scholar